Exact Mass: 496.199
Exact Mass Matches: 496.199
Found 500 metabolites which its exact mass value is equals to given mass value 496.199
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
7alpha-1(10->19)-Abeo-7-acetoxyobacun-9(11)-ene
7alpha-1(10->19)-Abeo-7-acetoxyobacun-9(11)-ene is found in citrus. 7alpha-1(10->19)-Abeo-7-acetoxyobacun-9(11)-ene is a constituent of the fruits of a Citrus-Poncirus hybrid Constituent of the fruits of a Citrus-Poncirus hybrid. 7alpha-1(10->19)-Abeo-7-acetoxyobacun-9(11)-ene is found in citrus.
(7R*,8R*)-3-Methoxy-3',4,7,9,9'-pentahydroxy-8,4'-oxyneolignan 4-xyloside
(7R*,8R*)-3-Methoxy-3,4,7,9,9-pentahydroxy-8,4-oxyneolignan 4-xyloside is a constituent of Pinus sylvestris (Scotch pine). Constituent of Pinus sylvestris (Scotch pine)
Selexipag
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents C78568 - Prostaglandin Analogue
(1R,4S,7R,8S)-7-[(2E,4E)-hexa-2,4-dienoyl]-3-hydroxy-8-[(2S)-3-hydroxy-2,4-dimethyl-5-oxo-2,5-dihydrofuran-2-yl]-5-[(2E,4E)-1-hydroxyhexa-2,4-dien-1-ylidene]-1,3-dimethylbicyclo[2.2.2]octane-2,6-dione
combretastatin B-1 2-beta-D-glucoside|combretastatin B-1 2-O-beta-D-glucopyranoside
trichodimerol
An organic heterotetracyclic compound found in Trichoderma longibrachiatum and Penicillium chrysogenum.
punaglandin 3
3-acetoxy-1,2;8,9-diepoxy-10-hexanoyloxy-2,3,6a,7,9,10,13a,14-octahydro-1H,8H-7a,14a-cyclo-pyrazino[1,2-a;4,5-a]diindole-6,13-dione|O-acetyl-O-hexanoyl-scabrosine|Scabrosin-4-acetat-4-hexanoat
N-Acetyl-D-glucosaminyl-(1-4)-N-acetylmuramic Acid
8alpha-(2-methyl)acryloylxy-13-methoxyvernojalcanolide
1,3,7,10-tetrahydroxy-8,8-dimethyl-4,11-bis(3-methyl-2-buten-1-yl)-6,7-dihydro-8H,13H-[1,4]benzodioxepino[2,3-d]benzopyran-13-one|oliveridepsidone B
3,10-bis-butyryloxy-1,2;8,9-diepoxy-2,3,6a,7,9,10,13a,14-octahydro-1H,8H-7a,14a-cyclo-pyrazino[1,2-a;4,5-a]diindole-6,13-dione|O,O-dibutyryl-scabrosine|Scabrosin-4,4-dibutyrat
(+)-arisugacin A|(4aR,6aR,12aR,12bS)-4a,6,6a,12,12a,12b-hexahydro-4a,12alpha-dihydroxy-4,4,6a,12b-tetramethyl-9-(3,4-dimethoxyphenyl)-4H,11H-naphtho[2,1-b]pyrano[3,4-e]pyran-1,11(5H)-dione|Arisugacin|arisugacin A
Tyr Ser Val Glu
C24H32O11_2-Propenoic acid, 2-methyl-, (4S,6R,6aS,9R,10S,10aR)-6,10-bis(acetyloxy)-4,5,6,6a,7,8,9,10-octahydro-6a,9-dihydroxy-3-(methoxymethyl)-6,9-dimethyl-2-oxo-2H-naphtho[8a,1-b]furan-4-yl ester
C28H32O8_(2E,4E,2E,4E)-1,1-[(1R,7S,10S)-1,6,8,13-Tetrahydroxy-3,7,10,14-tetramethyl-2,9-dioxapentacyclo[8.4.0.0~3,8~.0~4,14~.0~7,11~]tetradeca-5,12-diene-5,12-diyl]bis(2,4-hexadien-1-one)
(2E,4E)-1-[(1R,3S,8R,10S,14S)-12-[(2E,4E)-hexa-2,4-dienoyl]-1,6,8,13-tetrahydroxy-3,7,10,14-tetramethyl-2,9-dioxapentacyclo[8.4.0.0³,⁸.0⁴,¹⁴.0⁷,¹¹]tetradeca-5,12-dien-5-yl]hexa-2,4-dien-1-one
(1R,4S,7R,8S)-7-[(2E,4E)-hexa-2,4-dienoyl]-3-hydroxy-8-[(2S)-3-hydroxy-2,4-dimethyl-5-oxo-2,5-dihydrofuran-2-yl]-5-[(2E,4E)-1-hydroxyhexa-2,4-dien-1-ylidene]-1,3-dimethylbicyclo[2.2.2]octane-2,6-dione_major
(2E,4E)-1-[(1R,3S,8R,10S,14S)-12-[(2E,4E)-hexa-2,4-dienoyl]-1,6,8,13-tetrahydroxy-3,7,10,14-tetramethyl-2,9-dioxapentacyclo[8.4.0.0³,⁸.0⁴,¹⁴.0⁷,¹¹]tetradeca-5,12-dien-5-yl]hexa-2,4-dien-1-one_major
(2E,4E)-1-[(1R,3S,8R,10S,14S)-12-[(2E,4E)-hexa-2,4-dienoyl]-1,6,8,13-tetrahydroxy-3,7,10,14-tetramethyl-2,9-dioxapentacyclo[8.4.0.0³,?.0?,¹?.0?,¹¹]tetradeca-5,12-dien-5-yl]hexa-2,4-dien-1-one
Ala Glu Phe Met
Ala Glu Met Phe
Ala Phe Glu Met
Ala Phe Met Glu
Ala Met Glu Phe
Ala Met Phe Glu
Cys Asp Phe Ile
Cys Asp Phe Leu
Cys Asp Ile Phe
Cys Asp Leu Phe
Cys Glu Phe Val
Cys Glu Val Phe
Cys Phe Asp Ile
Cys Phe Asp Leu
Cys Phe Glu Val
Cys Phe Ile Asp
Cys Phe Leu Asp
Cys Phe Met Pro
Cys Phe Pro Met
Cys Phe Val Glu
Cys His His Thr
Cys His Thr His
Cys Ile Asp Phe
Cys Ile Phe Asp
Cys Ile Met Met
Cys Leu Asp Phe
Cys Leu Phe Asp
Cys Leu Met Met
Cys Met Phe Pro
Cys Met Ile Met
Cys Met Leu Met
Cys Met Met Ile
Cys Met Met Leu
Cys Met Pro Phe
Cys Pro Phe Met
Cys Pro Met Phe
Cys Thr His His
Cys Val Glu Phe
Cys Val Phe Glu
Asp Cys Phe Ile
Asp Cys Phe Leu
Asp Cys Ile Phe
Asp Cys Leu Phe
Asp Glu His Pro
Asp Glu Pro His
Asp Phe Cys Ile
Asp Phe Cys Leu
Asp Phe Ile Cys
Asp Phe Leu Cys
Asp His Glu Pro
Asp His Pro Glu
Asp Ile Cys Phe
Asp Ile Phe Cys
Asp Ile Ser Tyr
Asp Ile Tyr Ser
Asp Leu Cys Phe
Asp Leu Phe Cys
Asp Leu Ser Tyr
Asp Leu Tyr Ser
Asp Pro Glu His
Asp Pro His Glu
Asp Ser Ile Tyr
Asp Ser Leu Tyr
Asp Ser Tyr Ile
Asp Ser Tyr Leu
Asp Thr Val Tyr
Asp Thr Tyr Val
Asp Val Thr Tyr
Asp Val Tyr Thr
Asp Tyr Ile Ser
Asp Tyr Leu Ser
Asp Tyr Ser Ile
Asp Tyr Ser Leu
Asp Tyr Thr Val
Asp Tyr Val Thr
Glu Ala Phe Met
Glu Ala Met Phe
Glu Cys Phe Val
Glu Cys Val Phe
Glu Asp His Pro
Glu Asp Pro His
Glu Glu Tyr Gly
Glu Phe Ala Met
Glu Phe Cys Val
Glu Phe Asp Ser
Glu Phe Met Ala
Glu Phe Ser Asp
Glu Phe Thr Thr
Glu Phe Val Cys
Glu Gly Glu Tyr
Glu Gly Tyr Glu
Glu His Asp Pro
Glu His Pro Asp
Glu Met Ala Phe
Glu Met Phe Ala
Glu Pro Asp His
Glu Pro His Asp
Glu Ser Asp Phe
Glu Ser Phe Asp
Glu Ser Val Tyr
Glu Ser Tyr Val
Glu Thr Phe Thr
Glu Thr Thr Phe
Glu Val Cys Phe
Glu Val Phe Cys
Glu Val Ser Tyr
Glu Val Tyr Ser
Glu Tyr Asp Ala
Glu Tyr Glu Gly
Glu Tyr Gly Glu
Glu Tyr Ser Val
Glu Tyr Val Ser
Phe Ala Glu Met
Phe Ala Met Glu
Phe Cys Asp Ile
Phe Cys Asp Leu
Phe Cys Glu Val
Phe Cys Ile Asp
Phe Cys Leu Asp
Phe Cys Met Pro
Phe Cys Pro Met
Phe Cys Val Glu
Phe Asp Cys Ile
Phe Asp Cys Leu
Phe Asp Asp Thr
Phe Asp Glu Ser
Phe Asp Ile Cys
Phe Asp Leu Cys
Phe Asp Ser Glu
Phe Asp Thr Asp
Phe Glu Ala Met
Phe Glu Cys Val
Phe Glu Asp Ser
Phe Glu Met Ala
Phe Glu Ser Asp
Phe Glu Thr Thr
Phe Glu Val Cys
Phe Ile Cys Asp
Phe Ile Asp Cys
Phe Leu Cys Asp
Phe Leu Asp Cys
Phe Met Ala Glu
Phe Met Cys Pro
Phe Met Glu Ala
Phe Met Pro Cys
Phe Pro Cys Met
Phe Pro Met Cys
Phe Thr Glu Thr
Phe Thr Thr Glu
Phe Val Cys Glu
Phe Val Glu Cys
His Cys His Thr
His Cys Thr His
His Asp Glu Pro
His Asp Pro Glu
His Glu Asp Pro
His Glu Pro Asp
His His Cys Thr
His His Thr Cys
His Pro Asp Glu
His Pro Glu Asp
His Thr Cys His
His Thr His Cys
Ile Cys Asp Phe
Ile Cys Phe Asp
Ile Cys Met Met
Ile Asp Cys Phe
Ile Asp Phe Cys
Ile Asp Ser Tyr
Ile Asp Tyr Ser
Ile Phe Cys Asp
Ile Phe Asp Cys
Ile Met Cys Met
Ile Met Met Cys
Ile Ser Asp Tyr
Ile Ser Tyr Asp
Ile Tyr Asp Ser
Ile Tyr Ser Asp
Leu Cys Asp Phe
Leu Cys Phe Asp
Leu Cys Met Met
Leu Asp Cys Phe
Leu Asp Phe Cys
Leu Asp Ser Tyr
Leu Asp Tyr Ser
Leu Phe Cys Asp
Leu Phe Asp Cys
Leu Met Cys Met
Leu Met Met Cys
Leu Ser Asp Tyr
Leu Ser Tyr Asp
Leu Tyr Asp Ser
Leu Tyr Ser Asp
Met Ala Glu Phe
Met Ala Phe Glu
Met Cys Phe Pro
Met Cys Ile Met
Met Cys Leu Met
Met Cys Met Ile
Met Cys Met Leu
Met Cys Pro Phe
Met Glu Ala Phe
Met Glu Phe Ala
Met Phe Ala Glu
Met Phe Cys Pro
Met Phe Glu Ala
Met Phe Pro Cys
Met Ile Cys Met
Met Ile Met Cys
Met Leu Cys Met
Met Leu Met Cys
Met Met Cys Ile
Met Met Cys Leu
Met Met Ile Cys
Met Met Leu Cys
Met Pro Cys Phe
Met Pro Phe Cys
Met Pro Ser Tyr
Met Pro Tyr Ser
Met Ser Pro Tyr
Met Ser Tyr Pro
Met Tyr Pro Ser
Met Tyr Ser Pro
Asn Asn Ser Tyr
Asn Asn Tyr Ser
Asn Ser Asn Tyr
Asn Ser Tyr Asn
Asn Tyr Asn Ser
Asn Tyr Ser Asn
Pro Cys Phe Met
Pro Cys Met Phe
Pro Asp Glu His
Pro Asp His Glu
Pro Glu Asp His
Pro Glu His Asp
Pro Phe Cys Met
Pro Phe Met Cys
Pro His Asp Glu
Pro His Glu Asp
Pro Met Cys Phe
Pro Met Phe Cys
Pro Met Ser Tyr
Pro Met Tyr Ser
Pro Ser Met Tyr
Pro Ser Tyr Met
Pro Tyr Met Ser
Pro Tyr Ser Met
Ser Asp Ile Tyr
Ser Asp Leu Tyr
Ser Asp Tyr Ile
Ser Asp Tyr Leu
Ser Glu Val Tyr
Ser Glu Tyr Val
Ser Ile Asp Tyr
Ser Ile Tyr Asp
Ser Leu Asp Tyr
Ser Leu Tyr Asp
Ser Met Pro Tyr
Ser Met Tyr Pro
Ser Asn Asn Tyr
Ser Asn Tyr Asn
Ser Pro Met Tyr
Ser Pro Tyr Met
Ser Val Glu Tyr
Ser Val Tyr Glu
Ser Tyr Asp Ile
Ser Tyr Asp Leu
Ser Tyr Glu Val
Ser Tyr Ile Asp
Ser Tyr Leu Asp
Ser Tyr Met Pro
Ser Tyr Asn Asn
Ser Tyr Pro Met
Ser Tyr Val Glu
Thr Cys His His
Thr Asp Val Tyr
Thr Asp Tyr Val
Thr Glu Phe Thr
Thr Glu Thr Phe
Thr Phe Glu Thr
Thr Phe Thr Glu
Thr His Cys His
Thr His His Cys
Thr Thr Glu Phe
Thr Thr Phe Glu
Thr Val Asp Tyr
Thr Val Tyr Asp
Thr Tyr Asp Val
Thr Tyr Val Asp
Val Cys Glu Phe
Val Cys Phe Glu
Val Asp Thr Tyr
Val Asp Tyr Thr
Val Glu Cys Phe
Val Glu Phe Cys
Val Glu Ser Tyr
Val Glu Tyr Ser
Val Phe Cys Glu
Val Phe Glu Cys
Val Ser Glu Tyr
Val Ser Tyr Glu
Val Thr Asp Tyr
Val Thr Tyr Asp
Val Tyr Asp Thr
Val Tyr Glu Ser
Val Tyr Ser Glu
Val Tyr Thr Asp
Tyr Asp Ile Ser
Tyr Asp Leu Ser
Tyr Asp Ser Ile
Tyr Asp Ser Leu
Tyr Asp Thr Val
Tyr Asp Val Thr
Tyr Glu Ser Val
Tyr Glu Val Ser
Tyr Ile Asp Ser
Tyr Ile Ser Asp
Tyr Leu Asp Ser
Tyr Leu Ser Asp
Tyr Met Pro Ser
Tyr Met Ser Pro
Tyr Asn Asn Ser
Tyr Asn Ser Asn
Tyr Pro Met Ser
Tyr Pro Ser Met
Tyr Ser Asp Ile
Tyr Ser Asp Leu
Tyr Ser Glu Val
Tyr Ser Ile Asp
Tyr Ser Leu Asp
Tyr Ser Met Pro
Tyr Ser Asn Asn
Tyr Ser Pro Met
Tyr Thr Asp Val
Tyr Thr Val Asp
Tyr Val Asp Thr
Tyr Val Glu Ser
Tyr Val Ser Glu
Tyr Val Thr Asp
7Z-punaglandin 3
7alpha-1(10->19)-Abeo-7-acetoxyobacun-9(11)-ene
(7R*,8R*)-3-Methoxy-3',4,7,9,9'-pentahydroxy-8,4'-oxyneolignan 4-xyloside
Acutifolactone
(R)-(+)-(Diphenylphosphino)-2-isopropoxy-1,1-binaphthyl
(S)-(+)-(Diphenylphosphino)-2-isopropoxy-1,1-binaphthyl
Methylprednisolone Sodium Succinate
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D005938 - Glucocorticoids C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D000893 - Anti-Inflammatory Agents D000970 - Antineoplastic Agents D020011 - Protective Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Arisugacin A
An organic heterotetracyclic compound that is 4a,12a-dihydroxy-4,4,6a,12b-tetramethyl-4a,6,6a,12,12a,12b-hexahydro-4H,11H-benzo[f]pyrano[4,3-b]chromene-1,11(5H)-dione substituted by 3,4-dimethoxyphenyl group at position 9 (the 4aR,6aR,12aS,12bS steroisomer). Isolated from the culture broth of Penicillium, it acts as a selective inhibitor of acetylcholinesterase.
Isodrummondin D
A chromenol that is a derivative of filicinic acid and is isolated from the stems and leaves of Hypericum drummondii. It has been found to exhibit antibacterial activity against Gram-positive bacteria Staphylococcus aureus and Bacillus subtilis and the acid fast bacterium Mycobacterium smegmatis.
Drummondin D
A chromenol that is a derivative of filicinic acid and is isolated from the stems and leaves of Hypericum drummondii. It has been found to exhibit antibacterial activity against Gram-positive bacteria Staphylococcus aureus and Bacillus subtilis and the acid fast bacterium Mycobacterium smegmatis.
(2R)-2-[[(2S)-4-methyl-2-[5-(6-oxo-3H-purin-9-yl)pentoxycarbonylamino]pentanoyl]amino]-3-methylsulfanylpropanoic acid
(1R,4S,5Z,7R,8S)-7-[(2E,4E)-hexa-2,4-dienoyl]-3-hydroxy-8-[(2S)-3-hydroxy-2,4-dimethyl-5-oxofuran-2-yl]-5-[(2E,4E)-1-hydroxyhexa-2,4-dienylidene]-1,3-dimethylbicyclo[2.2.2]octane-2,6-dione
Selexipag
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents C78568 - Prostaglandin Analogue
[(4S,6R,6aS,9R,10S,10aR)-6,10-diacetyloxy-6a,9-dihydroxy-3-(methoxymethyl)-6,9-dimethyl-2-oxo-5,7,8,10-tetrahydro-4H-benzo[h][1]benzofuran-4-yl] 2-methylprop-2-enoate
(1S,3R,4R,6E,7R,8S,10R,11R,13E,14R)-3,10-dihydroxy-6,13-bis[(2E,4E)-1-hydroxyhexa-2,4-dienylidene]-1,4,8,11-tetramethyl-2,9-dioxapentacyclo[8.4.0.03,8.04,14.07,11]tetradecane-5,12-dione
[3-(4-Nitrophenyl)-4-oxochromen-7-yl] 4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate
2-[4-[(1-Cyclopentyl-5-tetrazolyl)-(6-quinolinyl)methyl]-1-piperazinyl]-1,3-benzothiazole
(3S)-3-cyano-3-[[[(2S)-1-[(2S)-3,3-dimethyl-1-oxo-2-[[oxo-[4-(trifluoromethyl)phenyl]methyl]amino]butyl]-2-pyrrolidinyl]-oxomethyl]amino]propanoic acid
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1,3-thiazol-2-ylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-thiazolylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1,3-thiazol-2-ylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-thiazolylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-thiazolylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-thiazolylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5R,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-thiazolylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-thiazolylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
(1S,3R,4S,8S,10R)-3,10-dihydroxy-6,13-bis[(2E,4E)-1-hydroxyhexa-2,4-dienylidene]-1,4,8,11-tetramethyl-2,9-dioxapentacyclo[8.4.0.03,8.04,14.07,11]tetradecane-5,12-dione
beta-D-Glcp3(1-carboxyEt)NAc-(1->4)-beta-D-GlcpNAc
An amino disaccharide consisting of N-acetyl-beta-D-glucosamine, substituted on O-3 with a 1-carboxyethyl group and linked (1->4) to a second N-acetyl-beta-D-glucosamine residue.
(1R,4S,5E,7R,8S)-7-[(2E,4E)-hexa-2,4-dienoyl]-3-hydroxy-8-[(2S)-3-hydroxy-2,4-dimethyl-5-oxofuran-2-yl]-5-[(2E,4E)-1-hydroxyhexa-2,4-dienylidene]-1,3-dimethylbicyclo[2.2.2]octane-2,6-dione
(1R,3R,4S,5Z,7R,8S)-7-[(2E,4E)-hexa-2,4-dienoyl]-3-hydroxy-8-[(2S)-3-hydroxy-2,4-dimethyl-5-oxofuran-2-yl]-5-[(2E,4E)-1-hydroxyhexa-2,4-dienylidene]-1,3-dimethylbicyclo[2.2.2]octane-2,6-dione
(5E)-7-[(2E,4E)-hexa-2,4-dienoyl]-3-hydroxy-8-(3-hydroxy-2,4-dimethyl-5-oxofuran-2-yl)-5-[(2E,4E)-1-hydroxyhexa-2,4-dienylidene]-1,3-dimethylbicyclo[2.2.2]octane-2,6-dione
(7R*,8R*)-3-Methoxy-3,4,7,9,9-pentahydroxy-8,4-oxyneolignan 4-xyloside
19-Ethenyl-18-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-2,4,6,8,10,15-hexaen-14-one
WZ4003
WZ4003 is the first potent and highly specific NUAK kinase inhibitor with IC50 of 20 nM/100 nM for NUAK1 (ARK5)/NUAK2, without significant inhibition on other 139 kinases.
(6as,12ar)-12a-hydroxy-9-{[(2e,5e)-7-hydroxy-3,7-dimethylocta-2,5-dien-1-yl]oxy}-2,3-dimethoxy-6,6a-dihydro-5,7-dioxatetraphen-12-one
6,10-bis(acetyloxy)-6a,9-dihydroxy-3-(methoxymethyl)-6,9-dimethyl-2-oxo-4h,5h,7h,8h,10h-naphtho[4a,4-b]furan-4-yl 2-methylprop-2-enoate
12a-hydroxy-9-[(7-hydroxy-3,7-dimethylocta-2,5-dien-1-yl)oxy]-2,3-dimethoxy-6,6a-dihydro-5,7-dioxatetraphen-12-one
5-[12-(bromomethylidene)-4-hydroxy-3,6,9-trimethyltetracyclo[6.6.1.0²,⁶.0¹¹,¹⁵]pentadeca-7,11(15)-dien-3-yl]-2-methylpentane-1,2,3,4-tetrol
[(3r,4s,5s)-3,4,5-trihydroxy-6-[2-(1-hydroxy-4-oxocyclohexyl)ethoxy]oxan-2-yl]methyl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
methyl 5,6-bis(acetyloxy)-7-[(1e)-4-chloro-2-hydroxy-2-(octa-2,5-dien-1-yl)-5-oxocyclopent-3-en-1-ylidene]heptanoate
4-(dimethylamino)-5-methoxy-6-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),17,20(27),21(26),22,24-decaene-3,18-diol
7-(hexa-2,4-dienoyl)-3,6,10-trihydroxy-11-(1-hydroxyhexa-2,4-dien-1-ylidene)-3,5,8,10-tetramethyltricyclo[6.2.2.0²,⁷]dodec-5-ene-4,9,12-trione
(3r)-deoxypumiloside
{"Ingredient_id": "HBIN009581","Ingredient_name": "(3r)-deoxypumiloside","Alias": "NA","Ingredient_formula": "C26H28N2O8","Ingredient_Smile": "C=CC1C2CC3C4=NC5=CC=CC=C5C=C4CN3C(=O)C2=COC1OC6C(C(C(C(O6)CO)O)O)O","Ingredient_weight": "496.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5204","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "11420564","DrugBank_id": "NA"}